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ABSTRACT: The current ethical and legal standards for human sub-
jects research do not adequately address human gene editing technol-
ogies, because scientific advancements in this field have outpaced reg-
ulatory policy. The Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR) technique allows the rewriting of life’s code, but is 
fraught with scientific and ethical quandaries. In particular, the genetic 
alteration of human embryos in vitro in China has caused worldwide 
repercussions. It is hard to predict the long-term effects of proposed 
edits, which raises an inquiry about whether it is appropriate for hu-
mans to purposely alter any aspect of their genetic future. Genome 
editing is moving too quickly for processes of critical reflection, such 
as law and regulation, to keep pace. The ethical, legal and social impli-
cations of the use of these technologies in humans remain uncertain. 
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The resultant tension within the existing framework calls into question 
the underlying values on which moral and legal norms repose. This article 
explores the implications for law, ethics, regulation and health policy. Bal-
ancing potential benefits against the risk of unintended harms will shape 
perspectives on whether and how to use these technologies. Responsible 
engagement with decision makers and stakeholders, among other things, 
will promote transparency, confer legitimacy, and improve policy making.
––––––––––––––––
Introduction
The crossover between ethics and adequate governance in science seems particu-
larly acute in the case of genome editing. The emerging technology has revolutionised 
genetics and marked a new generation in biomedical sciences. China has launched 
ground-breaking human clinical trials making use of the CRISPR gene editing tool. A 
Chinese scientist, Jiankui He, claimed to have used the technology to alter the DNA of 
two new babies in China. The practice exacerbates uncertainties that exist in applying 
governance systems and existing norms. The use of CRISPR puts pressure on the norma-
tive judgements enshrined in moral and legal codes. He’s claims highlight the immediate 
need to develop strong global consensus and legal frameworks on the ethical use of 
human genome editing. Given the unprecedented growth of technology and the current 
inadequacy of scientific governance, an inquiry arises as to whether societal values will 
be reflected in how genome editing is eventually applied in practice.
In response to this rapidly shifting global concern, this study proceeds in five parts 
to address challenges arising from questions about the ethical, legal and social implica-
tions (ELSIs) of genome editing.1 Part I looks at CRISPR’s pros and cons and ascertains 
theoretically whether He’s conduct represents a game changer or opens a Pandora’s Box. 
Part II explores ethical and social implications of using CRISPR, considers the theory of 
social licence underlying the relevant governance, and looks at the ethical and regulatory 
concerns that CRISPR has raised. This section also examines how ethical reflection and 
governance systems can engage effectively with the technology, and whether equitable 
access to technology is both warranted and available. Part III provides a critical analysis 
of the current legal framework on this topic in the Chinese context. China’s lax regu-
lation and enforcement results inevitably in ethical arbitrage. A variety of contributing 
factors will be discussed as well. Part IV refers to international norms in respect to the 
global challenge. Notably, enforcement makes a significant difference apart from the 
need for reaching international consensus. Part V considers how the implementation of 
germline procedures will interact with current and future societal discourse, institutions, 
1   Nuffield Council on Bioethics, ‘Genome Editing: An Ethical Review Section 3-Moral Perspectives’ 
(London, September 2016) <http://nuffieldbioethics.org/wp-content/uploads/Section-3-Moral-perspec-
tives.pdf> 115.
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and law. Some regulatory models are examined herein, which can address the ensuing 
scientific, socio-ethical and legal challenges. This section then moves to analyse the 
different levels and scope of regulation and the challenges of a global situation in which 
varying approaches to legislation express diverse ethical values. A model that might suit 
China’s situation will be explored. 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR): Pros 
and Cons 
A lab in the Massachusetts Institute of Technology (MIT) has managed to genetically 
alter human embryos.2 A new tool of CRISPR (Clustered Regularly Interspaced Short 
Palindromic Repeats) acts like molecular scissors, enables targeted genomic editing and 
more precise and efficient genetic modifications.3 It is considered as “the hallmark of a 
bacterial defence system,” serving as the immune system in bacteria.4 As a commentator 
asserted, the revolutionary technology has vast potential for improving human life, as 
“the biggest biotech discovery of the century.”5 An international consensus says that it is 
ethical to improve gene editing, but that it should not be used to establish a pregnancy.6 
It is essential to evaluate whether the anticipated benefits are reasonable with respect 
to the risk of adverse effects.
Pros and Cons 
Genome editing holds conceptually transformative medical potential.7 There are 
implications arising from the scope and scale of the techniques. Rewriting genes is 
fraught with scientific and ethical quandaries.8 The safety of gene editing on human 
beings has not been confirmed, and the treatment cannot be withdrawn if adverse ef-
fects are identified. Its mistakes would be amplified by their extension to innumerable 
future generations. It is the magnification of genetic harm that distinguishes germline 
editing from other types of intervention. While CRISPR has shown significant promise 
for treating disease, little is known about its long-term risks.9 The most obvious safety 
concerns are called ‘off-target’ mutations, representing unintended changes to the ge-
2  Steve Connor, ‘First Human Embryos Edited in U.S., Using CRISPR’ MIT Technology Review (29 
December 2017).
3  Guy Riddihough, ‘CRISPR-Cas9 Molecular Scissors’ (2016) 351 Science 867.
4  Samuel H. Sternberg, Hagen Richter, et al., ‘Adaptation in CRISPR-Cas Systems’ (2016) 61 Molecular 
Cell Review 797, 808.
5   Carl Zimmer, ‘Breakthrough DNA Editing Born of Bacteria’ Quanta Magazine (6 February 2015).
6   Jeanne Snelling and Mike King Jeanne Snelling and Mike King, ‘Rogue Scientist: The Human CRIS-
PR Experiment’ (Blog: Journal of Medical Ethics, 29 November 2018).  <https://blogs.bmj.com/medical-eth-
ics/2018/11/29/rogue-scientist-the-human-crispr-experiment/>.
7    John Loike, ‘Don’t Ban the Use of CRISPR in Embryos’ TheScientist (29 November 2018).
8   Preetika Rana, Amy Dockser Marcus and Wenxin Fan, ‘China, Unhampered by Rules, Races Ahead 
in Gene-Editing Trials’ The Wall Street Journal (21 January 2018).
9   Matthew Campbell, ‘China Shrinks from the Gattaca Age’ Bloomberg (5 December 2018).
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nome.10 Irresponsible practice might bring about unforeseen disastrous outcomes in 
the long run. Unwanted genetic conditions might be permanently removed, any unin-
tended consequences from altering the germ-line will be passed on though.11 Adverse 
effects might even be multiplied by reverberation across generations,12 which could be 
irreversible. 
Potential precise medication. Genome editing is an exciting technology to improve 
human health, given its nature in transformation. CRISPR can be used to treat genetic 
diseases and prevent extremely severe conditions being passed on to their descendants. 
Using it to selectively insert, delete or replace DNA is conducive to far greater precision. 
The ability to make precise changes to the genes of humans offers new ways to tackle 
global challenges in health. It is an attempt at an ultimate cure, since it treats disease 
at its very root.13 It might eliminate the root causes of hereditary human diseases, and 
even correct genetic errors or reduce the risk of disease.14 With the potential to perma-
nently eradicate certain genetic disorders, some assert CRISPR could bring about an 
end to some of humanity’s worst diseases. Instead of temporarily fixing defective cells 
through the introduction of corrected or functional genes, CRISPR promises to correct 
the defect in the reproductive cells, producing progenies that are free of the defective 
gene.15 Furthermore, genetic modification could open up possibilities to carry out pre-
ventative procedures before the body has even begun to exhibit symptoms of a given 
disease.16 However, explicit scientific standards have not been established to quantify 
off-target genome alterations.17
10   National Academies of Sciences, Engineering, and Medicine, Human Genome Editing: Science, Ethics, 
and Governance (Washington DC, National Academies Press, 2017) 122; Christopher Gyngell, Thomas 
Douglas and Julian Savulescu, ‘The Ethics of Germline Gene Editing’ (2017) 34 (4) Journal of Applied 
Philosophy 498, 513; Pinar Akcakaya, Maggie L. Bobbin, et al., ‘In vivo CRISPR Editing with no Detectable 
Genome-wide off-Target Mutations’ (2018) 561 Nature 416, 419.
11   Kelly E. Ormond, Douglas P. Mortlock, et al., ‘Human Germline Genome Editing’ (2017) 101 (2) 
American Journal of Human Genetics 167, 176.
12   National Academies of Sciences, Engineering, and Medicine, Human Genome Editing: Science, Ethics, 
and Governance (Washington DC, National Academies Press, 2017) 122.
13  Marcel Doerflinger, W. Leonard Forsyth, et al., ‘CRISPR/Cas9-The Ultimate Weapon to Battle Infec-
tious Diseases?’ (2017) 19 (2) Cellular Microbiology e12693.
14  ‘Explainer: CRISPR Technology Brings Precise Genetic Editing-And Raises Ethical Questions’ Con-
versation (26 March 2015).
15  ‘Explainer: CRISPR Technology Brings Precise Genetic Editing-And Raises Ethical Questions’ Con-
versation (26 March 2015).
16  Karin Christiansen, ‘Genome Editing: Are We Opening a Back Door to Eugenics?’ ScienceNodic (14 
November 2017).
17  National Academies of Sciences, Engineering, and Medicine, Human Genome Editing: Science, Ethics, 
and Governance (Washington DC, National Academies Press, 2017) 17-29.
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Furthermore, a theoretical issue remains unaddressed in the ambit of consequen-
tialism.18 An action to be selected should be the one that produces the best conse-
quences, with all factors taken into account.19 A major concern arises from uncertain 
consequences that germline changes could have on future generations. As some com-
mentators observed:
Philosophically or ethically justifiable applications for this technology, should any ever 
exist, are moot until it becomes possible to demonstrate safe outcomes and obtain 
reproducible data over multiple generations.20
It always takes years for a new discovery to be tested regarding its harms and 
benefits. The risks and benefits of technological interventions of such a kind should 
not be resolved as abstract moral issues by philosophers. In this regard, CRISPR might 
one day be useful for permanently eliminating genetic traits in the human species, but 
not without enormous risks.21
Safety.  Safety is paramount among the arguments against modifying the human 
germ line, which concern has not been adequately addressed. It is unrealistic to preclude 
some off-target effects, neither possible to avoid inflicting more harm than good on future 
humans.22 Changes in one gene that has been “knocked out” and replaced with another 
could have unforeseen and harmful effects elsewhere in the genome.23 In this vein, the 
genome editing may cause more damage to DNA, and its editing process may disrupt 
healthy genes. Likewise, the prospect of enhancements for future generations may be 
viewed as problematic, because it could change the properties of healthy embryos.24 
Adding genes instead of repairing them might interfere with the normal expression of 
other genes. It is necessary to demonstrate that the editing procedures will not lead 
to any significant increase in unintended variants.25 Governing the rapidly emerging 
technology through adequate assessment will reduce its associated risks. Higher safety 
18  Sarah Chan and John Harris, ‘Consequentialism without Consequences: Ethics and Embryo Re-
search. (2010) 19 (1) Cambridge Quarterly of Healthcare Ethics 61, 74.
19  Philip Gardiner ‘A Virtue Ethics Approach to Moral Dilemmas in Medicine’ (2003) 29 (5) Journal 
of Medical Ethics 297, 302.
20  Edward Lanphier, Fyodor Urnov, et al., ‘Don’t Edit the Human Germ Line’ (2015) 519 (7544) 
Nature 410, 411.
21  Laurie Garrett, ‘CRISPR: Transformative and Troubling’ (Council on Foreign Relations, 13 April 
2016)    <https://www.cfr.org/expert-brief/crispr-transformative-and-troubling>.
22   ‘Genome Editing: Are We Opening a Back Door to Eugenics?’ ScienceNordic (14 November 2017).
23  Noah Feldman, ‘Outrage Over Human Gene Editing Will Fade Fast’ Bloomberg (27 November 
2018).
24  Edward Lanphier, Fyodor Urnov, et al., ‘Don’t Edit the Human Germ Line’ (2015) 519 (7544) 
Nature 410, 411.
25   National Academies of Sciences, Engineering, and Medicine, Human Genome Editing: Science, Ethics, 
and Governance (Washington DC, National Academies Press, 2017) 111.
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standards need to be applied to gene editing research.26 However, for safety to be assessed 
requires years if not decades of studying how genes play out in a lifespan.
Germline interventions make changes that are heritable.27 Accordingly, it has 
sparked serious debate about the ethical implications of the heritable changes to human 
genetic code. Affecting all cells in an organism, the method allows precise editing of 
genes for targeted traits, which can be passed down to future generations.28 It is going to 
deeply affect the future generations, and even affect the make-up of species of the human 
being. The issue is that the standard of scientific governance varies across jurisdictions. 
Heritable genome editing interventions should only be permitted provided that legitimate 
and effective mechanisms are in place to redress those effects.29 The technology is so 
new that the potential risks to human subjects cannot possibly justify the hypothetical 
benefits. Scientists do not fully understand the scope of the unintended damage CRISPR 
may do to DNA elsewhere in the genome or how deactivating C-C chemokine receptor 
type 5 (CCR 5) might leave people vulnerable to other diseases.30 Disproportionate risks 
of editing the germline may outweigh the potential benefits. The benefits are at best 
hypothetical whereas the risks are high, which is partly unknowable.31 It is essential 
to weigh up the potential benefits, risks and harms, and evaluate off-target events and 
other potential side effects.32 A recent Chinese scandal has escalated the concerns. 
The China Case
China was first out of the block testing CRISPR on humans.33 A Chinese researcher, 
Jiankui He, recently claimed that he had created the first genetically engineered human 
babies in November 2018.34 He’s conduct would potentially alter the genetic makeup 
26   David Baltimore, Paul Berg, et al., ‘Biotechnology. A Prudent Path Forward for Genomic Engineer-
ing and Germline Gene Modification’ (2015) 348 Science 36, 38.
27  Ainsley Newson and Anthony Wrigley, ‘Being Human: The Ethics, Law, and Scientific Progress of 
Genome Editing’ (2016) 87 (1) The Australian Quarterly 3, 8.
28  Mary Todd Bergman, ‘Perspectives on Gene Editing’ The Harvard Gazette (9 January 2019).
29  Nuffield Council on Bioethics, ‘Human Embryo Culture, Discussions Concerning the Statutory 
Time Limit for Maintaining Human Embryo in Culture in the Light of Some Recent Scientific Develop-
ments’ (London, August 2017) <http://nuffieldbioethics.org/wp-content/uploads/Human-Embryo-Cul-
ture-web-FINAL.pdf> 137.
30  ‘The Era of Human Gene-Editing May Have Begun. Why That Is Worrying’ The Economist (1 De-
cember 2018).
31  J. Benjamin Hurlbut, Sheila Jasanoff and Krishanu Saha, ‘The Chinese Gene-Editing Experiment 
Was an Outrage. The scientific Community Shares Blame’ The Washington Post (29 November 2018).
32  Shixiong Zhang, Xiangtao Li, et al., ‘Synergizing CRISPR/Cas9 Off-Target Predictions for Ensemble 
Insights and Practical Applications’ (2019) 35 (7) Bioinformatics 1108, 1115.
33  Preetika Rana, Amy Dockser Marcus and Wenxin Fan, ‘China, Unhampered by Rules, Races Ahead 
in Gene-Editing Trials’ The Wall Street Journal (21 January 2018).
34  Gina Kolata, Sui-Lee Wee and Pam Belluck, ‘Chinese Scientist Claims to Use CRISPR to Make First 
Genetically Edited Babies’ The New York Times (26 November 2018).
Reassess the Law and Ethics of Heritable Genome Editing Interventions 121
of the human race.35 He’s development of the technique and the capability will result 
in that capability becoming widely available across borders. Germline mistakes made 
in China and inherited indefinitely will, in all probability, filter into the worldwide 
human genome affecting future generations. As such, it should be of concern to the 
whole world since people will be even more genetically interconnected in the future. 
Given a largely-unresolved dimension of science ethics, the use of CRISPR to modify 
human embryos has prompted a debate on the ethics of human genetic technologies.36
Responsible use of the CRISPR: More inquiries than answers. Responsible research 
will actualise CRISPR’s potential to cure those most devastating genetic diseases.37 
However, a question of unethical use has been perceived from the outset of the tech-
nology. He flouted conventions of safety and research ethics.38 Due to the absence of 
thorough oversight, his act constitutes a departure from a variety of ethical and legal 
norms that prevent use of this technology in human reproduction.39 Risks in the case 
have not been properly assessed. Many safety issues may have unintended irreversible 
effects that may not be known for years,40 and could even spark a dangerous immune 
reaction. He ignored the complex ethical problems related to creating and destroying 
human embryos. As Collins said: 
the concept of altering the human germline in embryos for clinical purposes has been 
debated over many years from many different perspectives, and has been viewed 
almost universally as a line that should not be crossed.41 
Similarly, a statement by an International Summit42 convened by the Science and Med-
icine Academies of the United States, the United Kingdom and China provides that:
It would be irresponsible to proceed with any clinical use of germline editing unless 
and until
35  Stefan Kunzelmann and Klaus Förstemann, ‘Reversible Perturbations of Gene Regulation after Ge-
nome Editing in Drosophila Cells’ (2017) 12 (6) PLoS ONE (28 June 2017).
36  Alice Park, ‘Experts Are Calling for a Ban on Gene Editing of Human Embryos. Here’s Why They’re 
Worried’ Time (13 March 2019).
37  John Loike, ‘Opinion: Don’t Ban the Use of CRISPR in Embryos’ The Scientist (29 November 2018)
38   ‘Germline Gene-Editing Research Needs Rules’ Nature (13 March 2019).
39   Jeanne Snelling and Mike King Jeanne Snelling and Mike King, ‘Rogue Scientist: The Human CRIS-
PR Experiment’ (Blog: Journal of Medical Ethics, 29 November 2018).
40  Preetika Rana, Amy Dockser Marcus and Wenxin Fan, ‘China, Unhampered by Rules, Races Ahead 
in Gene-Editing Trials’ The Wall Street Journal (21 January 2018).
41   Francis Collins, Statement of NIH Funding of Research Using Gene-Editing Technologies in Human Em-
bryos (Maryland, National Institutes of Health, 28 April 2015) <https://www.nih.gov/about-nih/who-we-
are/nih-director/statements/statement-nih-funding-research-using-gene-editing-technologies-human-em-
bryos>.
42  The National Academies of Sciences, Engineering, and Medicine (NASEM), ‘International Summit 
on Human Gene Editing’ (2015) <http://nationalacademies.org/gene-editing/Gene-Edit-Summit/>; Travis 
Germline, ‘Editing Dominated DNA Summit’ (2015) (350) Science 1299, 1300.
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(i) the relevant safety and efficacy issues have been resolved, based on appropriate 
understanding and balancing of risks, potential benefits, and alternatives; and
(ii) there is broad societal consensus about the appropriateness of the proposed 
application. Moreover, any clinical use should proceed only under appropriate reg-
ulatory oversight.43
The above approaches demonstrate that there is a considerable need to address 
the social and ethical implications of inherited genetic modifications. To establish safety 
and ethical consensus is the first imperative. It is sensible to demand strong evidence 
of safety and reasonable risk/benefit ratios before new technologies are made available 
clinically.44 He’s case heightened the global awareness about the uncertain risks and 
the need to regulate powerful new human biotechnologies. Of the utmost importance 
is to make responsible use of human germline modifications, in order to treat or cure 
human diseases.
A Game Changer vis-à-vis A Pandora’s Box. The concern is mainly focused upon the 
core of the ethical prohibition on modification of the human germline. The safety and 
efficacy have not been demonstrated sufficiently through research in human embryos.45 
Regalado observed that:
The genetic editing of a speck-size human embryo carries significant risks, includ-
ing the risks of introducing unwanted mutations or yielding a baby whose body is 
composed of some edited and some unedited cells.46
Once it becomes scientifically safe to proceed with human gene editing, the le-
gitimate ethical concern is likely to be outweighed by the ethical imperative to avoid 
disease.47 Given grave concerns regarding the ethical and safety implications, the clinical 
application in human embryos could have unpredictable effects on future generations, 
which is dangerous and ethically unacceptable. Problematically, there is no adequate 
pre-clinical data to justify a first-in-humans trial.48 The Chinese case raises questions 
43  National Academies of Sciences, Engineering, and Medicine (NASEM), Communicating Science Effec-
tively: A Research Agenda (Washington, DC: The National Academies Press, 2016) 9.
44  ‘Why Treat Gene Editing Differently in Two Types of Human Cells?’ The Conversation (7 December 
2015).
45  Nuffield Council on Bioethics, ‘Genome Editing: An Ethical Review Section 3-Moral Perspectives’ 
(London, September 2016) <http://nuffieldbioethics.org/wp-content/uploads/Section-3-Moral-perspec-
tives.pdf> 115.
46   Antonio Regalado, ‘Chinese scientists are creating CRISPR babies’ MIT Technology Review (25 No-
vember 2018).
47   Noah Feldman, ‘Outrage over Human Gene Editing Will Fade Fast’ Bloomberg (27 November 
2018).
48   Jeanne Snelling and Mike King, ‘Rogue Scientist: The Human CRISPR Experiment’ (Blog: Journal 
of Medical Ethics, 29 November 2018). <https://blogs.bmj.com/medical-ethics/2018/11/29/rogue-scien-
tist-the-human-crispr-experiment/>.
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about humanity, human identity, integrity and dignity.49 A new boundary in unethical 
behaviour has been crossed. The risks extend not only to the health and safety of the 
children, but also to the integrity of the social relationships.50 As discussed above, the 
potential harms may outweigh the benefits of altering the genome of an embryo. Ger-
mline editing changes reproductive cells, meaning that any alterations will remain in 
the gene pool and be passed to each subsequent generation. The changes are riskier 
because early mistakes could have lasting consequences on future generations, altering 
the inheritance permanently.51 It is implied that ethics are clearly not keeping pace with 
the development of the gene editing technologies in China. There is potential for mar-
ginalisation of persons, and the ways in which social inequalities could be reinforced 
by limited access to them.52 The Chinese trial practice should not proceed until a more 
equitable approach to setting the terms of debate is achieved. They should come up 
with guidelines at the international level, and avoid any possible large-scale negative 
implications for future generations.53 It is worth exploring how to address the issue from 
moral and ethical perspectives. 
Moral and Ethical Responses to Genome Editing
The process of human germline modification has been the subject of ethical de-
bates long before the technology existed. There has been little research of the critical 
ethical issues involved with the unknown risks in resulting future generations. An eth-
ical approach to risk calls for revaluations of the possible consequences.54 In addition, 
societal-level concerns are particularly acute with respect to genome-editing interven-
tions aimed at enhancing human capabilities.55 Wider issues of social justice remain 
unaddressed in terms of the equity in distributing its benefits.56 It is vital to give special 
consideration to possible negative effects that could cause discrimination, injustice or 
disadvantage in society. 
49  J. Benjamin Hurlbut, Sheila Jasanoff and Krishanu Saha, ‘The Chinese Gene-Editing Experiment 
Was an Outrage. The scientific Community Shares Blame’ The Washington Post (29 November 2018).
50   Anna Zaret, Editing Embryos: Considering Restrictions on Genetically Engineering Humans’ 
(2016) 67 Hastings Law Journal 1805, 1839.
51   National Scientific Council on the Developing Child, ‘Early Experiences Can Alter Gene Expression 
and Affect Long-Term Development’ (Working Paper No. 10, Centre on the Developing Child, Harvard 
University, 2010) <http://www.developingchild.net>.
52  Christine DiPasquale, ‘Gene Editing and Human Identity: Promising Advances and Ethical Chal-
lenges’ (15 April 2018). <https://www.aaas.org/news/gene-editing-and-human-identity-promising-ad-
vances-and-ethical-challenges>.
53   Reenita Das, ‘Gene Editing With CRISPR-Cas9: The Next Step In Human Evolution Will Be Worth 
$25 Billion By 2030’ Forbes (14 December 2017).
54  Greg Licholai, ‘Is CRISPR Worth the Risk?’ Yale Insights (21 August 2018).
55  National Academies of Sciences, Engineering, and Medicine, Human Genome Editing: Science, Ethics, 
and Governance (Washington DC, National Academies Press, 2017) 24.
56  Ainsley Newson and Anthony Wrigley, ‘Being Human: The Ethics, Law, and Scientific Progress of 
Genome Editing’ (2016) 87 (1) The Australian Quarterly 3, 8.
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Social Licence Theory 
Any innovation has an implicit responsibility towards society.57 The Universal Eth-
ical Code for Scientists recognises the responsibility corresponding to the ‘social licence 
to practise’ as one of its three cardinal principles.58 There is theoretic hazard in genome 
editing though. The concept of inherent dignity proposes to supply an objective ground 
for making distinctions between acceptable and unacceptable uses of technology.59 The 
use of these technologies must be regulated through ethical oversight. As a leading ethics 
watchdog,60 the Nuffield Council on Bioethics reiterates the value from a perspective 
of human rights as well. The effect of asserting human rights is essentially to mark out 
and defend limits of tolerable behaviour.61 People whose genomes that have been edited 
should be entitled to the full enjoyment of human rights.62 In this sense, the processes 
of ethical oversight should ideally reflect society’s shared values and norms, not merely 
as they pertain to informed consent, but as they pertain to our sensibilities about the 
right ways to care for next generations.63
Equitable Concerns: Exacerbating Social Inequities and Injustice 
Benefits from CRISPR innovation raise concerns and controversies about fairness 
and distributive justice across all layers of society.64 Such interventions could be used 
not just for treatment, but also for enhancement, of which the latter is accessible only 
57  Walter D. Valdivia and David H. Guston, ‘Responsible Innovation: A Primer for Policymakers’ 
(Centre for Technology Innovation at Brookings, May 2015)  <https://www.brookings.edu/wp-content/
uploads/2016/06/Valdivia-Guston_Responsible-Innovation_v9.pdf>.
58  Department for Business, Energy & Industrial Strategy (BEIS), ‘Rigour, Respect, Responsibility: A 
Universal Ethical Code for Scientists’ (London, 12 September 2007) <https://www.gov.uk/government/
publications/universal-ethical-code-for-scientists>.
59  Nuffield Council on Bioethics, ‘Genome Editing: An Ethical Review Section 3-Moral Perspectives’ 
(London, September 2016) <http://nuffieldbioethics.org/wp-content/uploads/Section-3-Moral-perspec-
tives.pdf> 28.
60   ‘Ethics Backing for Tailored Drugs’ BBC (23 September 2003); The Nuffield Council on Bioethics 
was established in 1991, and funded jointly by the Nuffield Foundation, the Medical Research Council 
(MRC) and The Wellcome Trust. It examines and reports on the ethical questions raised by advances in 
biological and medical research.
61  Nuffield Council on Bioethics, ‘Genome Editing: An Ethical Review Section 3-Moral Perspectives’ 
(London, September 2016) <http://nuffieldbioethics.org/wp-content/uploads/Section-3-Moral-perspec-
tives.pdf> 28.
62  Nuffield Council on Bioethics, ‘Human Embryo Culture, Discussions Concerning the Statutory 
Time Limit for Maintaining Human Embryo in Culture in the Light of Some Recent Scientific Develop-
ments’ (London, August 2017) <http://nuffieldbioethics.org/wp-content/uploads/Human-Embryo-Cul-
ture-web-FINAL.pdf> 145.
63  ‘CRISPR Babies Raise an Uncomfortable Reality-Abiding by Scientific Standards Doesn’t Guarantee 
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to a few rather than to everyone.65 The ability to modify people’s genes could lead to 
disparities between genetic haves and have-nots66 and further result in systematic dis-
advantage. This could make the CRISPR product available to only the world’s elites, 67 
which, in substance, not only exacerbates existing social inequalities, but also creates 
new ones. There is an impact on social, intergenerational or even global justice, that is, 
fair distribution of advantages or opportunities among different groups in a society.68 It 
remains uncertain how to ensure that the most vulnerable or marginalised sections of 
the population are not to be disadvantaged.
Aside from using gene-editing to tackle medical issues, He’s research raises the 
spectre of gene-editing enhancements. An enhancement would be a modification to a 
normative non-disease trait to make an improvement to it.69The distinction between 
treatment and enhancements and between normal functioning and disease remains 
vague.70 The lines between what are considered prevention and enhancement are not 
easily discernible in some cases.71 There is no clear line between disease treatment and 
enhancement.72 There is no ethical consensus as to how to define the blurry boundar-
ies, particularly, in the case of nontherapeutic enhancement.73 Permitting the practice 
could result in the creation of super humans who have an unfair genetic advantage over 
those unenhanced ones. Savulescu defends by referring to the principle of Procreative 
Beneficence, arguing that there are significant moral reasons to select the finest child.74 
Nevertheless, there is a range of moral arguments against selective technologies.75 The 
pursuit of the ‘perfection’ of human traits cannot be ethically justified, either. The ben-
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efits and harms of genome editing are not necessarily distributed equitably between all 
people.76 A variety of underlying factors, such as wealth may disproportionately affect 
certain group of people. It raises questions of social virtues, equity and justice, given 
that it would benefit the rich far more than the poor.77 Inevitably, commercialisation 
may extend many potential inequalities if patents through genome editing techniques 
take hold.78 As such, this technology could not be accessible to the vulnerable, which 
would increase existing undesired disparities. It could lead to new lines of discrimina-
tion between the genetically “perfected” and those left behind.79 This is against public 
policy that is justified to forestall negative personal and social consequences, such as 
exacerbating existing inequalities.80 
It is essential to ensure that the interests of those potentially marginalised receive 
adequate protection in accordance with principles of social justice. At the current stage, 
it is more appropriate to use CRISPR to change a disease-causing genetic in the reason-
able short term. Otherwise, efforts will lack legitimacy.81 The impact of social and health 
inequality needs to be considered to prevent uses which reinforce prejudice and worsen 
inequalities within societies.82 In certain circumstances, the ethical considerations need 
be settled by legal and regulatory authorities. 
The Lax Regulation and Enforcement in China
There is a “regulatory asymmetry” between the West and China, of which the latter 
has inadequate regulation and serious oversight. Under the existing framework, China’s 
regulations governing research ethics are not as stringent as they are in other parts of the 
world. In principle, clinical trials of somatic gene modifications are legally permissible 
within the terms and conditions set out in regulations.83 The lax ethical environment has 
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led many to consider China the “Wild East” in biomedical research.84 It is important to 
heed the warnings of the scientific community to develop legal and ethical parameters 
before the technology is developed. At such, China is supposed to regulate CRISPR in 
a manner that accounts for both the safety concerns and the ethical dilemmas.85
Legal and Regulatory Frameworks
While gene editing technologies have been developed, the laws related to their 
use are outdated. There is a legitimate concern in terms of He’s clinical trial. In China, 
there are no clear laws but guidelines in place to prevent these actions. Regulations 
clearly stipulate that gene manipulation on the human gamete, zygote and embryo for 
the purpose of reproduction is banned in China. It is the weak enforcement that com-
plicates the implementation of the regulations. 
Regulatory Guidelines 
The Technical Norms of Human Assisted Reproductive Technologies provides that “gene 
manipulation on human gametes and embryos is banned for the purpose of reproduc-
tion.”86  In 2003, China’s Ministry of Science and Technology (MoST) together with 
the Ministry of Health (MoH) issued the Ethical Guidelines for Human Embryonic Stem 
Cell Research.87 Similar to the UK’s Human Fertilisation and Embryology Act (HFEA 
1990), it prohibits the conduct of research on embryos after a period of 14 days begin-
ning with the day on which the process of creating the embryo began.88 The Guideline 
to in-vitro clinics bars clinical experiments which violate ethical or moral principles. 
In 2007, the MoH promulgated Measures for the Ethical Review of Biomedical Research 
Involving the Human Body (for Trial Implementation).89 The National Commission of 
Health and Family Planning (NCHFP) issued the Ethical Review of Biomedical Research 
Involving Humans.90 Notably, beneficence is to be addressed to promote patients’ welfare 
and consider the risk/benefit balance. It highlights that the risk should be controllable, 
and the patient’s benefits should be prioritised compared with the scientific research.91 
84  Yangyang Cheng, ‘China Will Always Be Bad at Bioethics’ Foreign Policy (13 April 2018).
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Recently, the NCHFP issued the Measures for the Administration of the Clinical Application 
of Medical Technologies (2018).92 Medical technologies shall be prohibited from being 
applied clinically, if they have major ethical concerns.93
One of the regulatory issues is informed consent arising from the uncertain con-
sequences that germline changes could have on future generations.94 Signed informed 
consent is considered a standard requirement ensuring that patients are fully informed 
of the benefits and adverse effects.95 The consent conditions are more complex, given 
the consent of the parents is not sufficient to exhaust the putative moral duty towards 
the future person.96 Any genetic manipulation of an embryo has to proceed with the 
understanding that the person who is affected cannot consent to the initiative.97 It is 
arguable that gene editing is unethical as the future generations that will inherit the 
altered DNA did not consent to the procedure nor its potential adverse effects.98 At 
present, the heritable gene editing may not involve fully-developed notions of informed 
consent. There may be little involvement of ethics review boards compared to practices 
within developed countries.99 
Concerns Still Remain Unaddressed
Even though the Ministry of Health (MoH) has issued ethical rules, the legal re-
sponsibility is unclear and the penalties are lenient. While MoH’s Guidelines provides 
that ethical reviews are based upon the principles of ethics accepted by the international 
community, the implementation of China’s legal and regulatory system has proved inef-
fective in practice.100 The Chinese Guidance is ambiguous, although it prohibits clinical 
research that breaches ethical or moral principles. It lacks enforcement mechanisms and 
92  Measures for the Administration of the Clinical Application of Medical Technologies came into 
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93  Measures for the Administration of the Clinical Application of Medical Technologies (2018) Article 
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provides few instructions for investigators.101 Apparently, He’s work flouted the 2003 
Regulations governing in vitro fertilisation, which bans the use of gene-manipulated 
embryos for reproduction. The approaches are silent on gene editing in adult humans 
where changes will not affect future generations.102 As a result, the ethics review pro-
cess is often reduced to a formality, which is always considered as “a rubber stamp.” 
Furthermore, Nulla poena sine lege is a fundamental principle of criminal law, which 
is closely related to a basic understanding of criminal justice in China.103 Only the law 
can define a crime and prescribe a penalty. Accordingly, the offences and corresponding 
penalties should be clearly defined by law, that is, no punishment without law. There is 
no legal regime to prohibit the implantation into a human a genetically modified egg or 
sperm or human embryo. There might be some international regulations, being soft law 
in nature, which is not legally-binding in terms of enforcement. Given China does not 
recognise judge-made law, the nulla poena sine lege as principle is adopted in China’s 
judicial practice. There is no law in China that covers gene editing on human embryos, 
and none of the Chinese laws detail the consequences of violating them. Despite the 
above Guidelines, there are no adequate laws to be applicable in He’s case. Unsurpris-
ingly, the NCHFP reported that He’s conduct had been in serious violation of relevant 
national regulations and creates a pernicious influence at home and abroad.104 China 
seems to rely primarily upon regulation, that is, the detailed administrative rules adopted 
pursuant to legislative direction and authority, which appears to be more responsive.105 
However, technology develops faster than regulatory codes and legal instruments, which 
renders it difficult to keep up with the ethical and social implications. Although the 
above-mentioned regulations allude to ethical review committees and respect for human 
dignity, they do not refer to modification of the human germline or provide for coercive 
enforceability, active monitoring or sanctions. In this regard, it is hardly justified if He 
were to be prosecuted for criminal liability.
Contributing Variables to Inadequate Governance
 China does not have efficient review and approval procedures in place. Its rel-
atively lax legal frameworks could be exploited by rogue researchers. There are many 
deeply-rooted factors that contribute to the inadequate governance and control. Among 
101  Yangyang Cheng, ‘China Will Always Be Bad at Bioethics’ Foreign Policy (13 April 2018).
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other things, the lack of transparency and public engagement contribute to the inefficient 
governance of China’s development in gene editing.106 
Transparency and Public Engagement
The changes brought about by gene-editing should not increase “disadvantage, 
discrimination or division in society” and such changes should not harm the welfare 
of the future person.107 It is essential to facilitate public engagement before any field 
testing.108 The ethical issues should be subject to a broad and inclusive societal debate 
on the framing, evaluation and prioritisation of societal challenges.109 Anyone subject 
to the jurisdiction has a legitimate interest in the debate, through which it can bring 
shared and competing values to the surface.110 Unlike the West where public debate 
tends to be more coherently orientated towards regulatory or parliamentary activities 
among a variety of stakeholders, there is little public engagement in China. 111 On 26 
February 2019, National Commission of Health and Family Planning (NCHFP) sought 
for public opinions about Regulations on Biomedical Experiments,112 which represents 
a meaningful beginning for public engagement in this controversial issue. Furthermore, 
the lax regulatory environment stems in part from lack of adequate awareness. More 
significantly, a top-down approach is well-proved efficient strategy to address the chal-
lenge. It is advised that China commit to transparency and public engagement in this 
scenario, which is indispensable for raising public awareness and fostering a coherent 
environment therein. It is viable to address a gap for policymakers in China who need 
to be well-informed about the ethical concerns and potential hazards of this technology. 
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Plausible Perception 
There are substantial implications over the potential competition in this cut-
ting-edge area. He’s clinical trial is partly driven by international technological com-
petition as well as China’s nationally-prioritised strategy. The trials align with China’s 
industrial policy.113 As part of its drive to place China on the global stage in a multitude 
of industries, China highlighted gene editing in a 2016 Five-Year-Plan.114 Such a system-
atic breach stems from a common perception that enforcement of stringent regulatory 
norms compromises research innovation.115 There is a regulatory asymmetry between 
the West and China, and the resulting legal playing field is uneven, ranging from es-
sentially unrestricted to a complete ban.116 Another factor normally neglected is that 
economic costs have not been well weighed against the medical and social costs incurred 
by CRISPR’s mistakes. Even so, competitive advantage may come into being due to the 
uneven playing field in regulating genome editing. The economic advantages of genome 
editing may readily lead to a rapid expansion of application of the technique. China 
could beat its counterparts to apply CRISPR pioneered in the West.117 There would be 
substantial economic implications of health economics arising from heritable genome 
editing interventions for health services.118 Unsurprisingly, some Chinese scientists 
pursue a “calculative balance of observing and subverting institutional constraints” to 
circumvent those toothless regulatory initiatives.119 Thus, laws and regulations may 
not provide substantial deterrence in the control and monitoring of research. This may 
also undermine efforts to control immoral research based on the CRISPR technology. 
The research is sometimes faced with a catch-22 scenario where advancement is not 
likely without facing enormous moral and ethical challenges.120 In response, the West 
will have to commit to developing a regulatory regime that is flexible enough to allow 
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them to build competitiveness, while strict enough to prevent unintended societal and 
ethical consequences.121
Institutional Void in Oversight 
The Chinese governance framework includes administrative measures, ethical 
guidelines, principles and technical norms and standards. Oversight is specified at three 
levels in China, that is, by laws, regulations and ministerial guidelines. The ministerial 
guidelines are most closely related to the issue under discussion, although they are 
enforceable only if mentioned in a law, regulation or administrative measure.122 The 
relevant governance is centralised under the National Commission of Health and Fam-
ily Planning (NCHFP), which is responsible for laws, regulations and policies related 
to the gene ethics. China does not have adequate abilities to regulate CRISPR. The 
breach may even be considered as an unsuccessful product of China’s regulatory and 
legal landscape. It is the lax regulatory environment that may have contributed to He’s 
gene-editing experiments.123 The dispersal of the regulatory oversight of gene editing 
lacks integration among a large number of government agencies.124 Inevitably, the regu-
latory frameworks do not function properly at a lower level, such as the implementation 
by provincial departments. Furthermore, genome editing should be licensed for clinical 
use only once risks of adverse outcomes have been assessed by a national authority.125 
However, the ethical governance has long been the Achilles’ heel of China’s scientific 
endeavour.126 In He’s clinical trial, the research even does not need national regulators’ 
approval. As Larson observed:
He took advantage of the loosely worded and irregularly enforced regulations and 
generous funding available today in China, in some cases skirting even local protocols 
and possibly laws.127
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China’s inability to adhere to international ethical norms in the knowledge system 
ends up harming itself.128
Ethical Arbitrage 
Laws in China around this kind of research are more lax than in the West. There 
is a substantial gap between the practice in China and that under an international 
standard. Similar to the forum shopping, this unlevelled playing field makes it possi-
ble for ethically controversial practices to migrate to more accommodating regulatory 
environments, which is abused by some opportunists.129 They may take advantage of 
China’s toothless regulations and their ambiguity to undertake those heavily-restricted 
clinical trials in their home countries.130 As practices move between jurisdictions across 
ethical thresholds, one likely consequence is a form of ‘ethical arbitrage’ that may have 
the effect of eroding these differences.131 The ethical gap is likely to be exploited due to 
a technological advantage. It would be possible if a technologically-advantaged party 
could cooperate with a Chinese researcher for the gene editing trial of such a kind. A 
Western scientist could even gain financial support in China when he cannot secure 
grants or approval for this most controversial project.132 Therefore, some factors must 
be taken into account while forging an established framework for healthcare ethics of 
heritable gene editing, such as autonomy, nonmaleficence and beneficence.133 A benefit/
harm balance needs to be maintained proportionate given all the gene editing involves 
some kind of harm inevitably. A scientist must avoid doing harm and endeavour to 
reduce risk reasonably. Patients’ welfare should be promoted with the risk-benefit ratio 
considered properly.134 
International Norms in Response to the Challenges
There is no international treaty that directly regulates the human genome or the 
possibilities for its modification. Given gene editing is not contained by borders, an 
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ethical debate is vital to the future viability of gene editing, particularly in an interna-
tional regulatory environment struggling to keep up.135 Effective regulatory oversight 
mechanisms have sufficient legal authority and enforcement capability.136 It remains a 
challenge to identify what principles or frameworks can provide effective oversight for 
gene editing, and further to assess the prospect of international harmonisation of pol-
icies. China may learn from those best practices to govern the controversial research. 
It is worth looking at the existing system of regulatory oversight and ethical norms 
around the world. 
Soft Law Without Teeth 
The introduction of intergenerational genome editing needs to consider a much 
broader range of norms and consequences. Global agreements are required as to exactly 
how gene editing is to be managed, so as to avoid the putatively undesirable moral and 
social consequences.137 Currently, there is a considerable need for international com-
munity to work out a framework with viable spill-over effect on enhancing the national 
legal and regulatory approaches.  It is reasonable for the global community to consider 
instantiating national and supranational regulations for the sake of future enforcement.138
International Initiatives 
There are a variety of universally accepted international documents including the 
Nuremburg Code,139 Helsinki Declaration,140 and CIOMS/WHO International Ethical 
Guidelines.141 The International Ethical Guidelines for Health-related Research Involving 
Humans reiterates that scientific value and respect for the rights of participants underpins 
the ethical conduct of research.142 The International Society for Stem Cell Research (ISS-
135   Tom Bangay, ‘Gene Editing: Can the Law Keep Up? (22 March 2017) <https://www.ibanet.org/
Article/NewDetail.aspx?ArticleUid=fc0bd200-63e1-472f-a6b9-c86440859b83>.
136   National Academies of Sciences, Engineering, and Medicine, Human Genome Editing: Science, Eth-
ics, and Governance (Washington DC, National Academies Press, 2017) 106.
137   Nuffield Council on Bioethics, ‘Genome Editing: An Ethical Review Section 3-Moral Perspectives’ 
(London, September 2016) <http://nuffieldbioethics.org/wp-content/uploads/Section-3-Moral-perspec-
tives.pdf> 27.
138   Carolyn Brokowski and Mazhar Adli, ‘CRISPR Ethics: Moral Considerations for Applications of a 
Powerful Tool’ (2019) 431 (1) Journal of Molecular Biology 88, 101.
139   The Nuremberg Code is a set of research ethics principles for human experimentation created as 
a result of the Nuremberg trials in 1947.
140   The Declaration of Helsinki (DoH) is the World Medical Association’s (WMA) best-known policy 
statement. The first version was adopted in 1964 and most recently at the General Assembly in October 
2013.
141   Council for International Organizations of Medical Sciences (CIOMS) and World Health Organi-
zation (WHO), ‘International Ethical Guidelines for Health-related Research Involving Humans’ (Geneva, 
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CR) provides that: “Until further clarity emerges on both scientific and ethical fronts, the 
ISSCR holds that any attempt to modify the nuclear genome of human embryos for the 
purpose of human reproduction is premature and should be prohibited at this time.”143
These international guidelines play an active role in ethical debate and establish-
ment of international norms.144 As discussed above, the Oviedo Convention focuses 
on the integrity of the inheritance of genetic endowment, whereas the United Nations 
Educational Scientific and Cultural Organization (UNESCO) focuses on the integrity 
of the ‘human genome’.145 The latter imposes an international ban on any gene-editing 
research in human embryos. The Universal Declaration on the Human Genome and 
Human Rights (UDHGHR) refers to the principles of dignity, diversity and equality, 
and supports the concept of the human genome as a symbol of humanity’s heritage.146 
UDHGHR mandates that practices contrary to human dignity should be forbidden. It 
suggests that practices like germ line interventions could be contrary to human dignity 
and should not be permitted.147 It is also worthy to put risk assessment and management 
into place adequately.  Important mechanisms for securing that the freedom of scientific 
research does not violate the rights of others include requirements for favourable risk 
or impact assessments, linked to the requirement for due diligence.148 A principle of 
intergenerational equity is well elaborated in international law, which calls on states 
to take into account the rights of future generations when undertaking activities that 
may affect them.149 For instance, the Declaration on the Responsibilities of the Present 
Generations towards Future Generations contains a reference to the protection of the 
human genome linked with the preservation of the human species.150 The principle 
143  The International Society for Stem Cell Research (ISSCR), ‘Guidelines for Stem Cell Research 
and Clinical Translation’ (2016) <http://www.isscr.org/docs/default-source/guidelines/isscr-guide-
lines-for-stem-cell-research-and-clinicaltranslation.pdf?sfvrsn=2> 8.
144  Organisation for Economic Cooperation and Development (OECD), ‘Gene Editing for Ad-
vanced Therapies: Governance, Policy and Society’ (2018) <https://www.oecd-ilibrary.org/indus-
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Committee (2018) <http://www.unesco.org/new/en/social-and-human-sciences/themes/bioethics/inter-
national-bioethics-committee/>; UNESCO International Bioethics Committee Report of the IBC on Up-
dating Its Reflection on the Human Genome and Human Rights (2015) <http://unesdoc.unesco.org/imag-
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147   The Universal Declaration on the Human Genome and Human Rights Article 11.
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149   Itziar de Lecuona and María Casado, et.al., ‘Gene Editing in Humans: Towards a Global and In-
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requires that states should take into account the need to preserve the human species 
in its diversity for future generations. International consensus is needed to reflect and 
affect the ‘moral fabric of society’ that should partly be reflected in norms of law and 
governance.151
Lack of International Standard 
Heritability of germline changes is a novel form of risk not adequately accounted 
for in current regulatory frameworks.152 Currently, it is the jurisdiction of individual 
countries that decides what to allow when it comes to gene editing. Given the lack of 
an internationally agreed-upon regulatory framework, there is a need for regulations on 
a cross-border level. The Chinese case has prompted calls for international regulation 
of CRISPR research, which can serve to orientate moral action.153 As Nuffield Council 
on Bioethics observed, what counts as normal is therefore a legitimate question but 
often one that is highly contested with regard to the extent to which norms are related 
to medical intervention and enhancement.154 The international community should 
strive to establish norms concerning acceptable uses of human germline editing and to 
harmonise regulations, in order to discourage unacceptable activities while advancing 
human health and welfare.155 As such, a shared global standard for this purpose should 
be put in place as soon as possible. 
International Framework vis-à-vis National Enforcement
It is significant to develop principles for editing reproductive cells, because the eth-
ical and social issues posed by human genome editing transcend national boundaries.156 
In principle, the use of CRISPR should live up to the existing norms and standards for 
normal functioning in a scientifically enlightened society.157 There are neither actual in-
ternational rules covering specifically gene editing, nor international regulatory agencies 
and future generations are fully safeguarded”; UNESCO Declaration on Science and the Use of Scientific 
Knowledge 1999 §39.
151   National Academies of Sciences, Engineering, and Medicine (NASEM), Human Genome Editing: 
Science, Ethics, and Governance (Washington, DC: The National Academies Press, 2017) 147-156.
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with the capacity to enforce legal and ethical use of genetic technologies.158 Although 
the legislative and regulatory frameworks have great normative value, no country has 
yet adopted CRISPR-specific regulations.159
Forum Shopping in Scenarios of Medical Tourism: The Regulatory Heaven
A regulatory haven could emerge that would tempt providers or consumers to 
travel to jurisdictions with more lenient or non-existent regulations to access the re-
stricted procedures.160 The phenomenon of medical tourism has thus come into being, 
which encompasses the search for faster and cheaper therapeutic options, as well as 
newer or less regulated interventions.161 Given this legal and regulatory asymmetry, it 
will be unlikely to control efficiently if the technical capabilities exist in more permissive 
jurisdictions.162 It is not viable to seek to address a transnational problem with national 
legislation, but it would be meaningful to reach international consensus on the use 
of this technology. Harmonisation across national borders is crucial to seek a prudent 
path forward for genomic engineering and germline gene modification.163 An optimum 
global governance purports to offer a procedurally legitimate solution to controversial 
inquiries in morally plural societies.164 This highlights significance of more proactive 
engagement with other countries and international institutions in the development of 
international norms.165 International dialogue along with governance should be pro-
moted with particular regard to heritable genome editing research and innovation.166
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At Stake is Enforcement
Global efforts should be aimed at developing and integrating legal strategies for the 
prevention and penalisation of unacceptable research.167 It makes sense that an interna-
tional platform can call for consensus regarding how to regulate the use of CRISPR. A 
purely regulatory approach will not suffice. The lack of functional enforcement system 
at international levels will inevitably slide into an institutional void. Such a regulatory 
framework relies largely upon whether the most effective enforcement will occur at a 
national or regional level ultimately. Otherwise, an international ban would only play 
a symbolic role, whereas a national one can regulate it through its direct control and 
levers.168 To a greater extent, it is up to national regulatory agencies to set up appropriate 
frameworks to govern the use of CRISPR. However, many countries lack the resources to 
enforce those well-established international regulations.169 Thus, the crucial question is 
not what rules were broken, but whose judgments about what is right and appropriate 
should rule the future.170 He’s case underscores the importance of Guidelines, rather 
than reactive prohibitions.171 A systematic overview of the embryo research performed 
on each national territory should be put in place, at least, at the current stage. During 
the implementation of the governance tools, ethical and regulatory considerations 
should distinguish clearly between clinical and research applications, and appreciate the 
particular set of ethical challenges surrounding research involving human embryos.172
Legal and Regulatory Frameworks: A Comparative Perspective
Gene editing technology is moving ahead of society’s ability to assimilate its impli-
cations to normative frameworks.173 The legal and regulatory response to advances in 
CRISPR continues apace, with different jurisdictions having different levels of flexibility 
to accommodate the latest development.174 There are enormous implications over the 
potential competition in this scenario. It is imperative that China learn from best prac-
tices of other countries in both statutory and institutional approaches. 
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Criminal Offences 
Germline human genome editing is a criminal offence in some countries which 
have specific statutes to robustly regulate the conduct. Australia has one of the strictest 
regulatory environments for gene editing research in the world.175 The Prohibition of 
Human Cloning Act (PHCA 2002) makes it illegal to alter the genomes of embryonic 
cells. The law permits certain types of embryo research subject to licence. Under the 
Regulation of Human Embryo Research Amendment Act 2006 (RHERAA, 2006) and 
PHCA 2002, germline modification is punishable by imprisonment for up to 15 years.176 
Similarly, research and clinical trials on gene editing are illegal in Canada. The conduct 
is forbidden even if germ cells will not actually be used to create a new life. The Assisted 
Human Reproduction Act (AHRA 2004) forbids a wide range of research and in vitro and 
in vivo germ line alterations,177 including the creation of embryos178 or chimeras.179 It 
is a criminal offense for using gene-editing tools on cells that could lead to heritable 
genetic change in humans.180 The AHRA 2004 states that: “No person shall knowingly 
[…] alter the genome of a cell of a human being or in vitro embryo such that the alter-
ation is capable of being transmitted to descendants.”181 
Penalties by law may lead to heavy fines and potentially incarceration, which plays 
a more deterrent role.182 For instance, sanctions range from a fine up to $500,000 to 
imprisonment up to 10 years.183 The severe penalties chill the research environment, 
which inevitably compromise the countries’ global competitiveness in the arena of gene 
editing, let alone its potential commercialisation. 
United States: Framework and Institutions 
The United State has rather a cautious approach when it comes to the use of bio-
technology in the context of human clinical trials.184 It does not have specific laws directly 
forbidding germline editing, but the country does have a robust regulatory machinery. 
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A complicated regulatory scheme makes it difficult to perform germline modification.185 
The Food and Drug Administration (FDA) and the Recombinant DNA Advisory Com-
mittee (RAC) at the National Institute of Health (NIH) are two main authorities that 
regulate gene transfer technology. The FDA has regulatory jurisdiction to deal with the 
controversial issue.186 First, the FDA regulations concerning the editing of somatic cells 
are implemented by the Recombinant DNA Advisory Committee (RAC).187 The NIH 
forbids federal funding of human germline editing, while the RAC only regulates organ-
isations that receive NIH funding.188 Second, there are funding restrictions on embryo 
research that might have a strong effect on the underlying basic science.189 Under the 
FDA’s comprehensive regulation and multiple laws, genome editing for embryos is not 
allowed for clinical use.190 The FDA does not accept applications for research in which 
human embryos are made to have heritable DNA changes. A Congressional Budget Bill 
2015 stated: “None of the funds made available by this Act may be used…in research 
in which a human embryo is intentionally created or modified to include a heritable 
genetic modification.”191
Furthermore, the Consolidated Appropriations Act of 2016 prohibits federal 
funding for such kind of research.192 The National Academies of Sciences, Engineering, 
and Medicine (NASEM) set down a position on heritable genome editing, filling out the 
spectrum of positions seeking a pathway to eventual translation into the clinic, which 
finally led to a consensus report in February 2017.193 As such, heritable genome edit-
ing is subject to a complex framework of laws and regulations at both state and federal 
levels. In addition, appropriate consideration of social concerns is also resolved within 
the context of civil rights jurisprudence and legal decisions.194 The strong regulatory 
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framework effectively prohibits modification to heritable code, although the US does 
not have a legal ban.
The EU’s Approaches
Gene editing methods can have off-target events with still unknown consequences, 
so the European Union (EU) has put in place stricter safety regulations. In 1997, thir-
ty-five countries signed and ratified the Convention on Human Rights and Biomedicine 
(Oviedo Convention), to limit alterations to the human genome.195 It provides that pre-
dictive genetic tests should be used only for medical purposes. Ambiguously, there is no 
consensus about whether genome modification should be permitted for the avoidance 
of serious disease.196 The Oviedo Convention does call for a prohibition below on the 
use of genetic engineering of the germline or changing the makeup of later generations: 
“an intervention seeking to modify the human genome may only be undertaken for 
preventive, diagnostic or therapeutic purposes and only if its aim is not to introduce 
any modification in the genome of any descendants.”197
The Convention does not take a stand on the acceptability of research on in vitro 
embryos.198 It appears that Article 13 prohibits heritable genome editing interventions. 
In practice, there is no prohibition, although there are limits on the use of genome ed-
iting involving human embryos for research purposes.199 More specifically, it does not 
allow interventions that lead to the birth of children with a modified genome. However, 
Article 18 (1) provides that if national law allows such research, it shall ensure adequate 
protection of the embryo. As such, the editing and transplantation procedure would be 
governed by national quality and safety legislation implementing the EU Tissues and Cells 
Directive, which also concerns the traceability of cells used for human application.200
The EU Clinical Trials Regulation also provides: “No gene therapy clinical trials 
may be carried out which result in modifications to the subject’s germ line genetic iden-
tity.”201 In May 2016, the EU revised its Clinical Trials Regulation (EU No 536/2014) and 
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maintained the view that gene therapy trials that result in alterations to an individual’s 
germline should continue to be prohibited. There is no room for the gene editing to 
be compatible in the clinical trials regime in a reproductive context.202 In this vein, ge-
nome editing might well fall within the definition of a ‘clinical study’.203 There should 
be no move to implement heritable genome editing interventions. In addition, the 
EU Biotechnology Directive states: “there is a consensus within the Community that 
interventions in the human germ line and the cloning of human beings offends against 
ordre public and morality.”204
Apart from the above official positions, there are some civil campaigns for a more 
responsible use of this technology. A group of European scientists founded the Association 
for Responsible Research and Innovation in Genome Editing (ARRIGE) to examine and 
provide guidance about the ethical use of genome editing.205 In addition, the Hinxton 
Group published a consensus statement in September 2015 calling, among other things, 
for a roadmap for research to establish the safety of genome editing for use in humans.206
The UK’s Permissive But Tightly-Controlled Safeguarding Regime 
The UK is often at the forefront of ethical reflection internationally,207 which regime 
is regulated but permissive. UK law does not currently permit any editing of heritable 
DNA-genetic information contained in an embryo, egg or sperm. Any gene-editing that 
would affect the germline would be unlawful.208 It is illegal to use genome editing on 
human cells and embryos that are intended for fertility treatments to result in pregnancy. 
All reproductive applications of gene editing are banned under the UK’s regulatory re-
gime. However, it is allowed for strictly controlled research purposes.209 The laws make 
a distinction between the research and reproductive applications of gene editing.210 This 
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is a similar approach to Australian laws that distinguish between the use of cloning for 
reproductive purposes and cloning for research. It bans such modifications for repro-
ductive purposes, but regulates research purposes via a licensing process overseen by 
the Human Fertilisation and Embryology Authority (HFEA 1990).211 Institutionally, the 
UK has a regulatory system established by legislation. The governance and oversight of 
human embryo research lies in the hands of authorities that are legally regulated.212 The 
use of genome editing in human embryos for research has been approved by the HFEA 
1990.213 In principle, it is only permitted in practice if licensed by the HFEA.214 Activities 
that cannot be licensed include using an embryo in treatment that is not a ‘permitted’ 
embryo as defined in the Act.215 Genome editing can be used in humans where the genetic 
change cannot be inherited, or in embryos that are used in research with no intention 
of implantation.216 Scientists are “only allowed to genetically edit human embryos for 
14 days for research purposes, after which they must be destroyed, and it is illegal to 
implant them into a womb.”217 This enables clearly beneficial research to proceed while 
preventing controversial applications.218 These mandatory requirements are enshrined 
in the HFEA 1990, which, when combined with the HFEA Code of Practice, sets out a 
framework for new technologies that is both flexible and unambiguous.219 
In sum, the UK has adopted a more permissive approach to germline modifications. 
Unlike Australia and Canada’s stringent laws, the UK takes a more regulatory approach 
to gene editing research. The framework offers guidance for establishing similar norms 
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and oversight mechanisms for genome editing of somatic cells.220 It takes a position that 
encourages prudence and transparency.221 The UK’s model provides an external structure 
and orientation. With regard to the Oviedo Convention 1997, the UK may have already 
gone beyond the prohibition in Article 13 by legalising and licensing mitochondrial 
donation.222 Notably, the UK has not signed the Oviedo Convention, which is the most 
relevant to heritable genome editing interventions. It is not a State Party to the Oviedo 
Convention and thus not bound by it. After all, it allows testing on embryos in the lab, 
but does not extend to allowing pregnancies to be induced via gene-editing. 
Which Model Suits China’s Situation?
As discussed above, laws governing gene editing vary, with some countries banning 
it outright and others, including China, having no or less clear policies.223 Civil law may 
offer less flexibility than that in common law jurisdictions, which, may alternatively 
leave much work to be addressed through Guidelines and judicial interpretations.224 
The gene editing has, de facto, been conducted as an open secret in China. A range of 
gene editing activities still goes on despite the existing governance frameworks. There 
is no clear law to regulate such attempts. In response to China’s case, legal and ethical 
checks on this erratic progression of science will be necessary now more than ever.225 To 
achieve adequate deterrence, a criminal liability scheme is indispensable, which is similar 
to those in the governance regimes of Australia and Canada. The imposition of criminal 
liability would not harm China’s competitive position in the world of biotechnology, 
but create a strong deterrent.226 He’s case also highlights the immediate need to develop 
strong international agreements on the ethical use of human genome editing, and the 
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necessity of strong legal frameworks surrounding what modifications are permitted.227 
At least, China should adopt and apply rigidly the 14-day rule, which draws a “legal 
and regulatory line in the sand” after which continued research on human embryos is 
forbidden.228 A new regulatory regime should be introduced to incorporate a licensing 
programme for human embryo research.229 Institutionally, China may take after the UK’s 
institutional innovation by creating a Chinese version of the HFEA, which works as an 
independent regulator of research involving human embryos and gametes.230
Conclusion
Genome editing has the potential to give rise to transformative technologies in the 
field of human reproduction. Ethical considerations with respect to the use of CRIPSR 
arise predominantly. Heritable genome editing interventions may be inherited by future 
generations, which should be subject to strict regulation and oversight. There is a consid-
erable need for more proactive rules governing such a transformative technology. Given 
the lack of an internationally agreed-upon regulatory framework, He’s case highlights 
the importance of instituting formal regulation of gene editing in China. Furthermore, a 
well-established system is highly demanded to define a global ethical code of conduct. It 
is similarly important to affirm and codify international principles for protecting human 
dignity. More significantly, regulatory oversight will need to include legal authority and 
enforcement capacity. It is essential to address the principles underlying governance, 
international governance perspectives and potential applications for germline editing. 
Notably, it is unrealistic to design a ‘one-size-to-fit-all’ mechanism though. In the direc-
tion toward global governance and shared responsibility, it would be prudent to allow 
heritable genome editing interventions to be initially licensed on a case-by-case basis, 
complemented with a criminal liability regime.
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